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Ann Arbor, Michigan
Although thrombolytic therapy for acute myocardial infarction
(MI) is recommended without regard for infarct location, treat-
ment results are less impressive for inferior than for anterior MI
because the amount of myocardium at risk is smaller and less
strategically located, and the mortality risk is lower. Whereas the
risks associated with anterior MI are relatively constant, high risk
subsets of patients with an inferior MI can be identified by simple
electrocardiographic criteria, including left precordial ST seg-
ment depression, complete atrioventricular heart block and right
precordial ST segment elevation. Unfortunately, none of the
placebo-controlled, randomized trials have analyzed the benefit of
thrombolytic therapy for inferior MI in high risk versus low risk
subsets.
Thrombolytic therapy should be more successful in reducing
infarct size and decreasing mortality in high risk patients with an
inferior MI. Thrombolytic therapy may not decrease hospital
mortality in low risk patients (baseline risk 2% to 4%) or those
with symptom duration >6 h. Whereas it is arguable whether
coronary angioplasty is superior to thrombolytic therapy in
anterior MI, there are no mortality data to support using angio-
plasty as a primary or rescue reperfusion strategy instead of
thrombolytic therapy in inferior MI, unless thrombolytic contra-
indications are present or the patient is in cardiogenic shock.
(J Am Coll Cardiol 1997;30:334–42)
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Five large placebo-controlled multicenter trials (1–5) have
convincingly demonstrated that thrombolytic therapy reduces
morbidity and mortality in acute myocardial infarction (MI).
The benefits have been consistent across almost all subset
analyses, justifying appeals to expand restrictive treatment
indications so that increasing numbers of patients might have
the opportunity for therapeutic benefit (6,7). One of the most
important, and still somewhat controversial, subsets is infarct
location. Whereas treatment efficacy has been universally
accepted for thrombolytic candidates with an anterior MI,
skepticism continues to exist regarding treating patients who
present with an inferior MI (8–10).
There are several possible explanations for the inconsis-
tency of opinion about treatment recommendations for acute
inferior MI: 1) Because mortality with inferior MI is half that
of anterior MI, many studies enrolling relatively small numbers
of patients have been statistically underpowered to detect a
treatment difference; 2) because the amount of myocardium at
risk is generally smaller and less strategically located with
inferior MI, the window of reperfusion opportunity is shorter
and is more likely to be obscured by trials including patients
with delayed treatment; 3) patients with inferior MI can be
classified by electrocardiographic criteria into high and low risk
categories compared with the more homogeneous risk associ-
ated with anterior MI. An increased proportion of low risk
patients enrolled in a trial will diminish the ability to show a
treatment benefit. 4) The critical omission in the early trials of
aspirin as adjunctive therapy for streptokinase (SK) has con-
fused the debate.
Mortality Results by Infarct Location
Anterior MI. The 21- to 35-day mortality results from the
large placebo-controlled multicenter trials (1–5) for patients
with anterior MI treated with intravenous thrombolytic ther-
apy are shown in Figure 1. The control group mortality rate
ranged from 14.2% to 20.6% (mean 18.1%) and was signifi-
cantly reduced with thrombolytic therapy, irrespective of sam-
ple size, time to treatment or omission of aspirin as adjunctive
therapy for SK. Similar results were found in small placebo-
controlled trials from the United States (11) and New Zealand
(12). In contrast, German investigators in the ISAM trial (13)
could not show a significant reduction in mortality rate with SK
therapy (9.2% vs. 9.7%) despite limiting symptom duration to
6 h; treating with aspirin, heparin and a warfarin derivative;
and preserving left ventricular function. The control mortality
rate in the ISAM trial was much lower than that in the other
trials. Either aggressive adjunctive therapy significantly de-
creased mortality or a lower risk group of patients was
enrolled.
Inferior MI. The 21- to 35-day mortality results for patients
with inferior MI (1–5) are shown in Figure 2. The control
group mortality rate ranged from 7.8% to 10.2% (mean 8.6%).
SK therapy without adjunctive aspirin had only a small impact
on mortality reduction (1,3). These poor results may be due to
lower patency rates and higher reocclusion rates than have
been documented for other treatment strategies. Several
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(14,15) but not all (16) studies have found that reperfusion
rates with SK are lower for inferior than for anterior MI. In
The Netherlands Interuniversity trial (8), where aspirin was
not given, the 1-year reinfarction rate after inferior MI was
21% versus 8% after anterior MI.
In contrast, when aspirin was added to SK (3), or when
anistreplase (2) or alteplase (4) was given, mortality was
significantly reduced in placebo-controlled trials. Results from
the LATE trial (5) suggest that the treatment window might be
6 h for inferior MI compared with 12 h for anterior MI. The
lack of treatment benefit seen in the Western Washington
Intravenous Streptokinase trial (11) can be explained by small
sample size (n 5 234), failure to use adjunctive aspirin therapy
and low mortality risk (1.8% in control patients). A reduced
mortality rate was demonstrated in the treatment group in the
New Zealand trial (3.0% vs. 8.7%) (12). The ISAM study (13)
demonstrated the same insignificant 0.5% mortality benefit
(4.2% vs. 4.7%) for inferior as for anterior MI. However, at 7
months the mortality rate was improved (10.2% vs. 14.2%) in
the ISAM trial (17), as it was after 6 months in the ASSET trial
(7.7% vs 12.8%) (4) and at 1 year in the AIMS trial (7.6% vs.
11.9%) (2). When the Fibrinolytic Therapy Trialists (FTT)
collaborative group (18) pooled results from nine placebo-
controlled studies enrolling .1,000 patients, the mortality
benefit was only 7.5% vs. 8.4%. The inclusion of patients with
low risk, uncertain indications and symptom duration .12 h
dilutes the potential mortality benefit that can be obtained
when patients with ongoing ischemic chest pain, ST segment
elevation and symptom duration ,6 h are treated.
ECG High Risk Subsets in Inferior MI
Whereas the risks associated with anterior MI are relatively
consistent, high risk subgroups of patients with inferior MI can
be identified by simple ECG criteria (19). These include
patients with left precordial ST segment depression, third-
degree atrioventricular (AV) block and right precordial ST
segment elevation.
Left precordial ST segment depression. The significance of
concomitant ST segment depression in patients with inferior
ST segment elevation from acute inferior MI has been exten-
sively investigated. Although some have suggested that these
are electrical reciprocal changes without anatomic or physio-
logic implications (20), and others have implicated anterior
wall ischemia due to left anterior descending coronary artery
disease (21), overwhelming evidence supports a larger mass of
ischemic myocardium perfused by a more extensive infarct-
related artery as the usual cause of the ECG abnormality (22).
In a consecutive series of patients undergoing acute coronary
arteriography, the infarct-related artery was more often the
right coronary artery (RCA) than the circumflex artery (79%
vs. 21%), but the precordial changes were more frequent with
circumflex infarct-related arteries (71% vs. 40%) (23). Precor-
dial ST segment depression occurs in ;50% of patients with a
first inferior MI (23). However, the changes can be attenuated
by right ventricular (RV) ischemia (24), preexisting precordial
ST segment elevation or reperfusion and usually resolve within
24 h (25). The magnitude of precordial ST segment depression
is positively correlated with the magnitude of inferior ST
segment elevation (26). The presence of these changes is
prognostically important because they are associated with
larger infarct size (22,25,27), lower left ventricular ejection
fraction (LVEF) (22,25) and more complications (21), includ-
ing death (22,25). Persistent precordial ST segment depression
is particularly important in this regard (27). Precordial ST
segment depression on hospital admission has also been
associated with a higher mortality rate during follow-up after
hospital discharge for up to 5 years (27,28).
Two placebo-controlled studies (29,30) have evaluated the
significance of precordial ST segment depression in patients
treated with thrombolytic therapy. The Netherlands Interuni-
versity trial (29) studied the value of the initial ECG in
predicting infarct size limitation in 488 patients by measuring
cumulative 72-h release of myocardial alpha-hydroxybutyrate
dehydrogenase (HBDH). Compared with conventionally
Figure 1. Anterior MI. Odds ratios and 95% confidence intervals (CI)
for reduction of 21- to 35-day mortality in the groups assigned to
thrombolytic therapy versus placebo. AIMS 5 APSAC Intervention
Mortality Study; ASSET 5 Anglo-Scandinavian Study of Early Throm-
bolysis; GISSI-1 5 Gruppo Italiano per lo Studio della Streptochinasi
nell’Infarto Miocardico; ISIS-2 5 Second International Study of
Infarct Survival; LATE 5 Late Assessment of Thrombolytic Efficacy;
SK/ASA 5 streptokinase/aspirin.
Abbreviations and Acronyms
AV 5 atrioventricular
ECG 5 electrocardiogram, electrocardiographic
HBDH 5 alpha-hydroxybutyrate dehydrogenase
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
MR 5 mitral regurgitation
PTCA 5 percutaneous transluminal coronary angioplasty
RCA 5 right coronary artery
RV 5 right ventricle, right ventricular
SK 5 streptokinase
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treated patients, infarct size limitation was shown with SK (no
aspirin) in both anterior MI (480 U/liter of HBDH) and
inferior MI (330 U/liter of HBDH). In inferior MI, .6 mm
versus #6 mm of summed ST segment elevation in leads II, III
and aVF was associated with better infarct size limitation (460
vs. 240 U/liter of HBDH), as was .4 mm versus #4 mm of
summed ST segment depression in leads I, aVL and V1 to V6
(430 vs. 260 U/liter of HBDH). Note that the benefit in
patients with an inferior MI and more extensive ECG abnor-
malities was similar to the median infarct size limitation in
patients with anterior MI.
The European Cooperative Study Group (30) performed a
similar study in 655 patients treated with aspirin, intravenous
heparin and either alteplase or placebo. The summed amount
of both ST segment elevation and depression measured 60 ms
after the J point had a linear relation with cumulative HBDH
release, LVEF and hospital mortality. In inferior MI, treat-
ment benefit when summed precordial ST segment depression
was .5.5 mm versus #5.5 mm was associated with greater
HBDH reduction (234 vs. 137 U/liter of HBDH) and better
LVEF preservation (3.6% vs. 2.5%). Importantly, the hospital
mortality rate was reduced from 6.8% to 1.9% by alteplase in
patients with a precordial ST segment depression sum
.5.5 mm; the mortality rate was reduced only from 1.7% to
1.1% when the sum was #5.5 mm.
The Thrombolysis and Angioplasty in Myocardial Infarc-
tion (TAMI) study group (15) noted a higher complication rate
and a worse ventriculographic outcome in inferior MI despite
reperfusion therapy when precordial changes were present.
These results have been confirmed by the Global Utilization of
Streptokinase and Tissue Plasminogen Activator for Occluded
Coronary Arteries (GUSTO-I) study in .16,000 patients (31).
Moreover, hospital and 1-year mortality rates were higher
when precordial changes were present in the GUSTO-I study
(31).
Thus, it appears that thrombolytic therapy is most likely to
reduce infarct size and mortality in patients with inferior MI
when precordial ST segment depression is present. A similar
benefit would also be expected when concomitant ST segment
elevation or depression is present in the lateral leads. Patients
without precordial or lateral changes have such a good prog-
nosis (hospital mortality rate 2% to 4%) that it is unlikely that
thrombolytic therapy will alter their 30-day mortality rate.
AV heart block. Berger and Ryan (19) reviewed the pub-
lished data before 1989 and documented third-degree AV
block in 12% of patients with acute inferior MI, with an
additional 7% having second-degree AV block. More recent
reports (32,33) with equivalent sample sizes have noted a
similar incidence of third-degree AV block. The onset is
gradual in 50% of patients, according to Berger and Ryan (19),
and abrupt in the other 50%. Two-thirds of the patients who
develop AV block do so within the first 24 h (19,34). Mortality
rates are high for third-degree AV block (29% to 37% vs. 6%
to 14% without AV block (19,32,33) but are not elevated with
second-degree AV block (35) compared with patients without
AV block. Mortality appears to be due to larger infarct size
rather than directly related to the electrical abnormality or to
concomitant multivessel disease (19,34). Unfortunately, only a
few studies have addressed the issue, which contrasts with
published data on precordial ST segment depression.
Nicod et al. (34) noted greater creatine kinase enzyme
release (1,840 vs. 1,322 IU/liter) in patients with AV block. A
lower LVEF was documented by Kaul et al. (36) (49% vs.
55%) and Strasberg et al. (37) (51% vs. 58%). Importantly,
;50% of patients with third-degree AV block have RV MI
(36,37), which may contribute to their poor prognosis. Others
have demonstrated higher rates of atrial and ventricular ar-
rhythmias, congestive heart failure and cardiogenic shock
(32,33). However, hospital survivors have the same LVEF as
patients who do not develop third-degree AV block (34), and
there is no increased risk for subsequent mortality (32–34).
The explanation for this paradox may be that whereas precor-
dial ST segment depression predicts a larger ischemic area at
risk for infarction, third-degree AV block may be a common
marker of the larger infarctions that result in pulmonary
edema, cardiogenic shock and acute mortality. A recent report
(38) demonstrating rapid and lasting restoration of normal
sinus rhythm after injection of the adenosine antagonist the-
ophylline (100 mg/min to a maximum of 250 mg) suggests that
third-degree AV block is a metabolic complication rather than
an ischemic complication.
Four reports (39–42) have evaluated the impact of throm-
bolytic therapy in patients with AV block. Clemmenson et al.
(39) noted a 13% (50 of 373) incidence of third-degree AV
block in patients with a inferior MI; the mortality rate was 20%
compared with 4% in patients without third-degree AV block
despite thrombolytic therapy. Berger et al. (40) found a 12%
(214 of 1,796) incidence of second-degree or third-degree AV
block in a lower risk group of patients with inferior MI. The
mortality rate was 7.1% versus 2.7% when AV block was
absent. The relative risk for mortality for patients with AV
block receiving thrombolytic therapy in each study was equiv-
alent to that from the prethrombolytic era (19,32,33), and
LVEF values in survivors again were not influenced by the
Figure 2. Inferior MI. Odds ratios and confidence intervals for
reduction of 21- to 35-day mortality in the groups assigned to
thrombolytic therapy versus placebo. Abbreviations as in Figure 1.
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development of AV block. This finding supports the concept
that AV block is a complication of the larger infarction rather
than predictive of a larger ischemic area, where reperfusion
might be expected to salvage myocardium and reduce mortal-
ity. Alternatively, thrombolytic therapy may be ineffective in
reducing mortality in the large number of patients who present
with third-degree AV block and have associated hypotension
(43) or shock (44) or who develop third-degree AV block after
thrombolytic therapy due to failure to reperfuse or because of
infarct-related artery reocclusion.
McNeill et al. (41) initiated very early thrombolytic treat-
ment in 20 patients, and no deaths occurred. Duration of AV
block was much less than in their prethrombolytic era experi-
ence, confirming the same observation by Clemmenson et al.
(39). In a preliminary report, Maggioni et al. (42) found a
10.4% incidence of third-degree AV block in 4,194 patients
treated with thrombolytic therapy in the GISSI-2 trial. These
patients had a 15-day mortality rate of 12.8% versus 4.5% in
patients without third-degree AV block.
Thus, although third-degree AV block is associated with
larger infarct size and increased risk for in-hospital morbidity
and mortality, the present data do not clearly demonstrate that
thrombolytic therapy reduces the relative risk of mortality. The
absolute mortality reduction with thrombolytic therapy is not
known because thrombolytic trials exclude a large number of
high risk patients who are included in observational studies.
Right precordial ST segment elevation. Right coronary
artery thrombosis proximal to the RV branches or proximal
occlusion of a dominant circumflex artery produces right
precordial ST segment elevation and RV dysfunction in ;40%
of patients with inferior MI (45). Fifty percent of these patients
have no clinical abnormalities, despite right precordial ECG
ST segment elevation or RV echocardiographic abnormalities,
whereas 50% have hemodynamic perturbations. The most
serious hemodynamic complication is cardiogenic shock, which
occurs in 3% to 8% of patients with inferior MI (46–48). The
mortality rate in eight studies reporting on 58 patients with RV
myocardial infarction and shock was 34% (46,48–54), approx-
imately half that reported for left ventricular myocardial
infarction with shock. Other complications of RV myocardial
infarction include high degree AV block in as many as 50% of
patients, rupture of the interventricular septum, thrombus
formation and subsequent pulmonary embolism, refractory
hypoxemia due to right to left interatrial shunting through a
patent foramen ovale or atrial septal defect and tricuspid
regurgitation (45). In-hospital mortality for RV myocardial
infarction is rare, unless cardiogenic shock is present. Long-
term prognosis is predominantly determined by left ventricular
function but appears to be worsened by the combination of
both right and left ventricular dysfunction (55,56).
Isolated RV free wall ischemia seldom disturbs cardiac
function, but several associated factors can lead to hemody-
namic impairment (57,58). Occlusion of the RCA branches to
the right atrium produces ischemic right atrial dilation and
dysfunction. Right atrial volume and pressure overload impede
venous return to the atrium and optimal filling of the RV.
Similarly, loss of atrial function due to atrial fibrillation or AV
dysynchrony are electrical complications that compromise the
preload-dependent RV. RV stroke volume is also dependent
on heart rate such that bradyarrhythmias due to sinus node
dysfunction or the Bezold-Jarisch reflex decrease cardiac out-
put. Finally, ischemic dysfunction of global left ventricular
contraction, interventricular contraction or the crista su-
praventricularis muscle bundle in the RV diminish systolic
ventricular interactions that compensate for RV dysfunction.
The hemodynamic abnormalities resulting from RV dysfunc-
tion include disproportionate elevation of right-sided filling
pressures, systemic hypotension and low cardiac output.
RV dysfunction in the setting of inferior MI is predomi-
nantly due to ischemia rather than infarction. In the absence of
reperfusion therapy, many (59–60) but not all (61–62) studies
have shown substantial improvement in RV ejection fraction in
the majority of patients over a few days to several weeks. The
improvement is probably due to resolution of ischemic dys-
function secondary to spontaneous reperfusion of the RCA or
to the development of collateral circulation. The ability of the
RV to tolerate prolonged ischemia better than the left ventri-
cle was demonstrated in an elegant study by Schofer et al. (63).
Intracoronary thallium scintigraphy was performed before and
after thrombolysis in 11 patients. RV thallium defects detected
before thrombolysis were reversible. The determination of
myocardial necrosis by technetium-99m accumulation in the
RV was seen in three of eight patients versus left ventricular
accumulation in seven of eight patients.
The RV is less prone to infarction than the left ventricle
because of a more favorable oxygen supply–demand relation.
Several factors increase oxygen supply: 1) The thin-walled RV
has a lower coronary vascular resistance, with minimal com-
pression of the microvasculature during systole. This and a
relatively higher coronary artery/RV end-diastolic pressure
gradient result in both systolic and diastolic coronary blood
flow in the RV as opposed to predominantly diastolic flow in
the left ventricle (64). 2) The left anterior descending coronary
artery contributes 25% of the right ventricular free wall blood
flow (65). 3) RV transmural perfusion is more homogeneous,
whereas left ventricular ischemia causes disproportionate sub-
endocardial ischemia. 4) Potential collateral flow from the left
main coronary artery to the RCA is about three times that
available in the opposite direction (66). 5) Direct perfusion
from the RV cavity through the thebesian venous system is
possible (67), but the concept has been challenged (68).
Oxygen demand is reduced in the RV compared with the left
ventricle because it has one-sixth the muscle mass, performs
one-fourth the stroke work and ejects against one-tenth the
afterload (69).
The ability to tolerate prolonged RV ischemia without
necrosis should make these patients attractive candidates for
reperfusion. Unfortunately, only scant data exist from small
studies (60–62,70). In patients achieving reperfusion, the RV
ejection fraction was improved by 24 to 48 h and improved
further at later time points. The presence of RV wall motion
abnormalities on predischarge radionuclide ventriculography
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in the TIMI-II study (71) was strongly associated with an
occluded infarct-related artery (42% vs. 13% with a patent
infarct-related artery), suggesting that early patency facilitates
early recovery of RV function. The influence of thrombolytic
therapy on mortality in patients with RV MI was not examined
in the placebo-controlled thrombolytic trials.
Left Ventricular Function
The effect of thrombolytic therapy on left ventricular func-
tion can be assessed by evaluating infarct size, end-systolic
volumes and LVEF.
Infarct size. The measurement of myocardial infarct size
has been accomplished using enzymatic and scintigraphic
techniques (Table 1). Thrombolytic therapy produces a reduc-
tion in infarct size in both anterior and inferior MI (14,72–75).
End-systolic volume. End-systolic volume has been proven
to be an important prognostic variable (76). In the Interuni-
versity Trial (77), SK therapy resulted in significantly lower
end-systolic volumes in both anterior (45 vs. 60 ml/m2) and
inferior MI (37 vs. 48 ml/m2). Similarly, White et al. (12)
documented significantly lower end-systolic volumes in both
anterior (61 vs. 85 ml) and inferior MI (53 vs. 64 ml) with SK
therapy.
LVEF. Several placebo-controlled trials (12,73–75,77–81)
have reported LVEF results by infarct location using either
radionuclide or contrast ventriculography (Table 2). LVEF in
inferior MI is higher than in anterior MI, in keeping with the
concept that better LVEF is associated with lower mortality
risk. Preservation of LVEF occurs in both anterior and inferior
MI, although the benefit is somewhat greater for anterior MI,
presumably because of the larger amount of ischemic myocar-
dium at risk.
Thus, although the risk of mortality from inferior MI is half
that of anterior MI, and the mortality reduction with throm-
bolytic therapy in inferior MI is approximately half that in
anterior MI, the salutary effects on ventricular function due to
thrombolytic therapy are more equivalent.
Mitral Regurgitation
Significant mitral regurgitation (MR) is an important com-
plication of acute MI because it is associated with an increased
risk of heart failure and death (82). MR has been found by
auscultation in 17% to 55%, echocardiography in 20% to 50%
and contrast ventriculography in 5% to 20% of patients with an
acute MI, but severe MR occurs in ,5% (82). Normally,
systolic contraction of the papillary muscles maintains coapta-
Table 1. Infarct Size Reduction After Thrombolytic Therapy
Study (ref no.) No. of Pts Time Method of Detection
Infarct Size Reduction
Ant MI Inf MI
van der Laarse et al. (72) 495 3 days Enzymes 34% 31%
Ritchie et al. (73) 100 8 wk SPECT 17% 31%
Ritchie et al. (74) 207 8 wk SPECT 15% 19%
Schroder et al. (14)
,3 h 389 2 days Enzymes 16% 14%
,6 h 651 2 days Enzymes 10% 4%
Bassand et al. (75) 231 3 wk SPECT 33% 16%
Ant 5 anterior; Inf 5 inferior; MI 5 myocardial infarction; Pts 5 patients; ref 5 reference; SPECT 5 single-photon
emission computed tomography.
Table 2. Left Ventricular Ejection Fraction After Thrombolytic Therapy
LVEF (%)
No. of Pts Ant MI Inf MI
Study (ref no.) Ant MI Inf MI Lytic Agent Route Time Method Lytic Control D Lytic Control D
Ritchie et al. (73) 89 118 SK IC 8 wk RNA 41 37 14 52 49 13
Ritchie et al. (74) 64 141 SK IV 8 wk RNA 43 37 16 54 52 12
Serruys et al. (77) 148 184 SK IC/IV 2 wk Contrast 50 43 17 57 49 18
White et al. (12) 64 91 SK IV 3 wk Contrast 57 49 18 60 55 15
Guerci et al. (78) 53 80 rt-PA IV 10 days RNA 45 33 112 59 54 15
O’Rourke et al. (79) 57 69 rt-PA IV 3 wk Contrast 57 47 110 66 59 17
NHFA (80) 40 61 rt-PA IV 1 wk Contrast 53 40 113 62 57 15
Bassand et al. (75) 88 121 APSAC IV 4 days Contrast 47 40 17 56 51 15
Meinertz et al. (81) 144 169 APSAC IV 2–3 wk Contrast 53 54 21 60 61 21
APSAC 5 anisoylated plasminogen–streptokinase (SK) activator complex; IC 5 intracoronary; IV 5 intravenous; LVEF 5 left ventricular ejection fraction;
NHFA 5 National Heart Foundation of Australia; RNA 5 radionuclide angiogram; SK 5 streptokinase; rt-PA 5 recombinant tissue-type plasminogen activator; D 5
change; other abbreviations as in Table 1.
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tion of the leaflets and prevents prolapse of the valve into the
left atrium. Ischemia of the papillary muscle can cause diastolic
lengthening or decreased systolic shortening, leading to leaflet
prolapse. Alternatively, regional dyssynergy of the left ventric-
ular segment at the base of a papillary muscle or alteration of
the normal spatial geometry of the papillary muscles and the
chordae tendineae due to left ventricular dilation can compro-
mise leaflet coaptation.
Whereas the anterolateral papillary muscle is perfused by
the diagonal branches of the left anterior descending coronary
artery and the obtuse marginal branches of the circumflex
artery, the posteromedial papillary muscle is perfused only by
the posterior descending artery and is thus more vulnerable to
ischemic dysfunction or rupture. Therefore, posterolateral MI
is more common in patients with acute ischemic MR. Clinical
predictors of developing acute ischemic MR include female
gender, older age, previous MI, multivessel disease, a large MI
and an occluded infarct-related artery (82–85).
The impact of reperfusion therapy on preventing ischemic
MR has not been clearly elucidated. Lehmann et al. (83)
reported no benefit in the TIMI trial, where 206 patients
initially had angiographic occlusion of the infarct-related ar-
tery before thrombolytic therapy. However, they excluded 13
of 27 patients with initial MR because those patients did not
have repeat contrast ventriculography before discharge, and
they added 7 patients to the analysis who had late, but not
early, MR. In contrast to the mild MR studied by Lehmann et
al. (83), Tcheng et al. (82) described 50 patients with moder-
ately severe to severe MR from 1,480 consecutive patients
undergoing acute cardiac catheterization at Duke University.
They also described no benefit with reperfusion therapy, but
only 23 patients received early thrombolytic therapy, and only
22 of the remaining 32 patients underwent percutaneous
transluminal coronary angioplasty (PTCA).
The most rigorous report comes from Leor et al. (86) who
studied 104 patients with a first inferior MI. Thrombolytic
therapy was given to 55 patients; the 49 patients ineligible for
thrombolytic therapy formed the control group. Treated pa-
tients had a marked reduction in moderate to severe MR
measured by pulsed Doppler echocardiography at 24 h (4% vs.
16%), 7 to 10 days (11% vs. 24%) and 28 to 30 days (7% vs.
15%). Severe MR developed in five patients in the control
group but in no patients in the treatment group. In a follow-up
study (87), improvement in posterobasal segment function was
associated with a decreased incidence of significant MR.
Although Tcheng et al. (82) reported no benefit with PTCA
in a high risk group of patients, anecdotal resolution of acute
MR after PTCA has been documented (84,86–89).
Percutaneous Transluminal
Coronary Angioplasty
Primary PTCA. PTCA is an attractive reperfusion strategy
relative to thrombolysis because of high patency rates, excel-
lent restoration of normal coronary flow characteristics, ab-
sence of contraindications, decreased recurrent ischemic
events and freedom from intracerebral hemorrhage (90). Pa-
tency rates do not appear to be influenced by arterial distribu-
tion (91), although as with thrombolytic therapy, reocclusion
rates may be slightly higher in inferior MI (91). Transient
hypotension or bradycardia, or both, at the time of reperfusion
(the Bezold-Jarish reflex) can occur during RCA reperfusion.
Whereas atropine is often unsuccessful in overcoming this
reflex, an intravenous injection of 1 to 2 mg of metaraminal
quickly restores hemodynamic stability.
The major limitation of direct PTCA is immediate access to
an excellent cardiac catheterization laboratory with expert
interventionalists. Although it can be claimed that PTCA in
anterior MI produces lower mortality rates than thrombolysis,
no survival benefit has been seen in inferior MI (92). However,
rapid hemodynamic improvement has been noted after suc-
cessful PTCA in patients with RV MI (93), and arrhythmias
and AV block frequently resolve (94). PTCA appears to be
superior to thrombolysis in patients with cardiogenic shock
(44).
Rescue PTCA. Lower success rates and higher reocclusion
rates result from rescue PTCA than with primary PTCA (95).
This finding undoubtedly is due to more complicated index
lesions in which thrombolysis has already failed. An increased
incidence of ventricular fibrillation, AV block and bradycardia/
hypotension complicate procedures in the RCA but can easily
be treated if the interventionalist is prepared to address them
quickly (96,97). There are no data suggesting that mortality
rates are reduced by rescue PTCA in inferior MI. In fact, the
Randomized Evaluation of Salvage Angioplasty With Com-
bined Utilization of Endpoints (RESCUE-I) trial (98) enrolled
only patients with a moderate or large anterior MI in an
attempt to perform a positive study.
Conclusions
Thrombolytic therapy reduces infarct size, preserves left
ventricular function and decreases mortality in patients with an
inferior MI. The ECG can be used to stratify patients into high
risk (precordial ST segment depression, third-degree AV
block, RV MI) or low risk (isolated ST segment elevation in
leads II, III, aVF) subsets. Unfortunately, none of the placebo-
controlled trials have analyzed the benefit of thrombolytic
therapy in high risk versus low risk subjects. Data from other
studies suggest that thrombolytic therapy should be most
useful in patients at higher clinical risk and with larger
potential infarct size (precordial ST segment depression [99],
ST segment elevation in more than three leads [100], RV MI),
but it is not clear that there is therapeutic benefit in patients
with isolated ST segment elevation in leads II, III and aVF or
symptoms .6 h.
Whereas it is arguable whether PTCA is superior to throm-
bolytic therapy in anterior MI, there are no mortality data to
support using PTCA as a primary or rescue reperfusion
strategy in inferior MI instead of thrombolytic therapy, unless
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thrombolytic contraindications are present or the patient is in
cardiogenic shock or perhaps congestive heart failure.
The GUSTO-I trial (101) demonstrated a superior survival
benefit for alteplase compared with SK that was more impor-
tant for anterior MI (19 lives saved/1,000 patients) than
inferior MI (6 lives saved/1,000 patients). Assuming that
patients with high risk or a complicated inferior MI have a
mortality rate more similar to those with an anterior MI,
alteplase would seem to be the favored thrombolytic strategy.
Conversely, because mortality rates with uncomplicated infe-
rior MI are low, it may not matter which thrombolytic agent is
used from a mortality standpoint, although earlier reperfusion
with alteplase would more likely salvage ischemic myocardium.
Although thrombolytic therapy for patients with a low risk
inferior MI may decrease infarct size and preserve left ventric-
ular function, it may not decrease hospital mortality rates
because the baseline risk is only 2% to 4%. With the risk of
intracerebral hemorrhage constant and increasing scrutiny
directed toward therapeutic cost-effectiveness, the risk/benefit
(102) and cost/benefit ratios of administering thrombolytic
therapy to low risk patients with inferior MI should be
revisited.
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